-+ 0.00%
-+ 0.00%
-+ 0.00%

Roth Capital Initiates Coverage On Exagen with Buy Rating, Announces Price Target of $8

Benzinga·06/25/2026 10:28:38
Listen to the news
Roth Capital analyst Max Masucci initiates coverage on Exagen (NASDAQ:XGN) with a Buy rating and announces Price Target of $8.